Global Elrantamab Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Elrantamab market size was valued at US$ 313 million in 2025 and is forecast to a readjusted size of US$ 1153 million by 2032 with a CAGR of 12.6% during review period.
Elranatamab is a humanized bispecific monoclonal antibody targeting BCMA/CD3, indicated for the treatment of relapsed or refractory multiple myeloma. The drug can simultaneously bind to BCMA antigen on the surface of myeloma cells and CD3 antigen on the surface of T cells. By bridging tumor cells and T cells, it activates T cells to specifically kill tumor cells. As a T-cell redirecting immunotherapeutic agent, it is characterized by high targeting specificity and significant anti-tumor activity.In 2025, global Elranatamab production reached approximately 51000??52000 vials.
Elranatamab is a humanized bispecific monoclonal antibody targeting BCMA/CD3, mainly used for the treatment of relapsed or refractory multiple myeloma, and is one of the core agents in the field of T-cell redirecting immunotherapy. With a clear mechanism of action, it activates anti-tumor immunity by bridging myeloma cells and T cells. Clinical studies have confirmed that it exhibits deep and durable efficacy in heavily pretreated patients, and is recommended by authoritative guidelines such as the US NCCN and Chinese CSCO, with a clear market positioning.
In terms of the competitive landscape, the drug, together with similar BCMA/CD3 bispecific antibodies including Johnson & Johnson?s Teclistamab, constitutes an important therapeutic option for multiple myeloma, while facing competition from CAR-T therapies. Its differentiation is reflected in its administration route and tolerability profile. Elranatamab has been approved in major markets worldwide including the United States, the European Union and China, with commercial layout covering multiple regions. Continuous clinical development, including combination therapies and exploration of first-line indications, provides long-term momentum for market expansion.
As an important layout of Pfizer in the field of tumor immunology, the drug relies on the company?s marketing channels and R&D resources, and is expected to occupy an important position in the bispecific antibody market for multiple myeloma. Meanwhile, it will promote the popularization and application of BCMA-targeted therapeutic regimens and become a key force in innovating the treatment landscape of this field.
This report is a detailed and comprehensive analysis for global Elrantamab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Elrantamab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Elrantamab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Elrantamab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Elrantamab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Elrantamab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Elranatamab is a humanized bispecific monoclonal antibody targeting BCMA/CD3, indicated for the treatment of relapsed or refractory multiple myeloma. The drug can simultaneously bind to BCMA antigen on the surface of myeloma cells and CD3 antigen on the surface of T cells. By bridging tumor cells and T cells, it activates T cells to specifically kill tumor cells. As a T-cell redirecting immunotherapeutic agent, it is characterized by high targeting specificity and significant anti-tumor activity.In 2025, global Elranatamab production reached approximately 51000??52000 vials.
Elranatamab is a humanized bispecific monoclonal antibody targeting BCMA/CD3, mainly used for the treatment of relapsed or refractory multiple myeloma, and is one of the core agents in the field of T-cell redirecting immunotherapy. With a clear mechanism of action, it activates anti-tumor immunity by bridging myeloma cells and T cells. Clinical studies have confirmed that it exhibits deep and durable efficacy in heavily pretreated patients, and is recommended by authoritative guidelines such as the US NCCN and Chinese CSCO, with a clear market positioning.
In terms of the competitive landscape, the drug, together with similar BCMA/CD3 bispecific antibodies including Johnson & Johnson?s Teclistamab, constitutes an important therapeutic option for multiple myeloma, while facing competition from CAR-T therapies. Its differentiation is reflected in its administration route and tolerability profile. Elranatamab has been approved in major markets worldwide including the United States, the European Union and China, with commercial layout covering multiple regions. Continuous clinical development, including combination therapies and exploration of first-line indications, provides long-term momentum for market expansion.
As an important layout of Pfizer in the field of tumor immunology, the drug relies on the company?s marketing channels and R&D resources, and is expected to occupy an important position in the bispecific antibody market for multiple myeloma. Meanwhile, it will promote the popularization and application of BCMA-targeted therapeutic regimens and become a key force in innovating the treatment landscape of this field.
This report is a detailed and comprehensive analysis for global Elrantamab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Elrantamab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Elrantamab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Elrantamab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Elrantamab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Elrantamab
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Elrantamab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- 44 mg / 1.1 mL
- 76 mg / 1.9 mL
- Subcutaneous Injection Solution
- Lyophilized Powder for Injection
- Hospital
- Retail
- Online
- Monoclonal Antibody
- Polyclonal Antibody
- Bispecific Antibody
- Monotherapy for Relapsed or Refractory Multiple Myeloma
- Combination Therapy with Immunomodulators and Proteasome Inhibitors
- Exploration in First-Line or Second-Line Treatment of Multiple Myeloma
- Otherts
- Pfizer
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
- Chapter 1, to describe Elrantamab product scope, market overview, market estimation caveats and base year.
- Chapter 2, to profile the top manufacturers of Elrantamab, with price, sales quantity, revenue, and global market share of Elrantamab from 2021 to 2026.
- Chapter 3, the Elrantamab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
- Chapter 4, the Elrantamab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
- Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
- Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Elrantamab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
- Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
- Chapter 13, the key raw materials and key suppliers, and industry chain of Elrantamab.
- Chapter 14 and 15, to describe Elrantamab sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Elrantamab Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 44 mg / 1.1 mL
1.3.3 76 mg / 1.9 mL
1.4 Market Analysis by Dosage Form
1.4.1 Overview: Global Elrantamab Consumption Value by Dosage Form: 2021 Versus 2025 Versus 2032
1.4.2 Subcutaneous Injection Solution
1.4.3 Lyophilized Powder for Injection
1.5 Market Analysis by Sales Channels
1.5.1 Overview: Global Elrantamab Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
1.5.2 Hospital
1.5.3 Retail
1.5.4 Online
1.6 Market Analysis by Antibody Type
1.6.1 Overview: Global Elrantamab Consumption Value by Antibody Type: 2021 Versus 2025 Versus 2032
1.6.2 Monoclonal Antibody
1.6.3 Polyclonal Antibody
1.6.4 Bispecific Antibody
1.7 Market Analysis by Application
1.7.1 Overview: Global Elrantamab Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.7.2 Monotherapy for Relapsed or Refractory Multiple Myeloma
1.7.3 Combination Therapy with Immunomodulators and Proteasome Inhibitors
1.7.4 Exploration in First-Line or Second-Line Treatment of Multiple Myeloma
1.7.5 Otherts
1.8 Global Elrantamab Market Size & Forecast
1.8.1 Global Elrantamab Consumption Value (2021 & 2025 & 2032)
1.8.2 Global Elrantamab Sales Quantity (2021-2032)
1.8.3 Global Elrantamab Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Elrantamab Product and Services
2.1.4 Pfizer Elrantamab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Pfizer Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: ELRANTAMAB BY MANUFACTURER
3.1 Global Elrantamab Sales Quantity by Manufacturer (2021-2026)
3.2 Global Elrantamab Revenue by Manufacturer (2021-2026)
3.3 Global Elrantamab Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Elrantamab by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Elrantamab Manufacturer Market Share in 2025
3.4.3 Top 6 Elrantamab Manufacturer Market Share in 2025
3.5 Elrantamab Market: Overall Company Footprint Analysis
3.5.1 Elrantamab Market: Region Footprint
3.5.2 Elrantamab Market: Company Product Type Footprint
3.5.3 Elrantamab Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Elrantamab Market Size by Region
4.1.1 Global Elrantamab Sales Quantity by Region (2021-2032)
4.1.2 Global Elrantamab Consumption Value by Region (2021-2032)
4.1.3 Global Elrantamab Average Price by Region (2021-2032)
4.2 North America Elrantamab Consumption Value (2021-2032)
4.3 Europe Elrantamab Consumption Value (2021-2032)
4.4 Asia-Pacific Elrantamab Consumption Value (2021-2032)
4.5 South America Elrantamab Consumption Value (2021-2032)
4.6 Middle East & Africa Elrantamab Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global Elrantamab Sales Quantity by Type (2021-2032)
5.2 Global Elrantamab Consumption Value by Type (2021-2032)
5.3 Global Elrantamab Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Elrantamab Sales Quantity by Application (2021-2032)
6.2 Global Elrantamab Consumption Value by Application (2021-2032)
6.3 Global Elrantamab Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Elrantamab Sales Quantity by Type (2021-2032)
7.2 North America Elrantamab Sales Quantity by Application (2021-2032)
7.3 North America Elrantamab Market Size by Country
7.3.1 North America Elrantamab Sales Quantity by Country (2021-2032)
7.3.2 North America Elrantamab Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Elrantamab Sales Quantity by Type (2021-2032)
8.2 Europe Elrantamab Sales Quantity by Application (2021-2032)
8.3 Europe Elrantamab Market Size by Country
8.3.1 Europe Elrantamab Sales Quantity by Country (2021-2032)
8.3.2 Europe Elrantamab Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Elrantamab Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Elrantamab Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Elrantamab Market Size by Region
9.3.1 Asia-Pacific Elrantamab Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Elrantamab Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Elrantamab Sales Quantity by Type (2021-2032)
10.2 South America Elrantamab Sales Quantity by Application (2021-2032)
10.3 South America Elrantamab Market Size by Country
10.3.1 South America Elrantamab Sales Quantity by Country (2021-2032)
10.3.2 South America Elrantamab Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Elrantamab Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Elrantamab Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Elrantamab Market Size by Country
11.3.1 Middle East & Africa Elrantamab Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Elrantamab Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Elrantamab Market Drivers
12.2 Elrantamab Market Restraints
12.3 Elrantamab Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Elrantamab and Key Manufacturers
13.2 Manufacturing Costs Percentage of Elrantamab
13.3 Elrantamab Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Elrantamab Typical Distributors
14.3 Elrantamab Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Elrantamab Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 44 mg / 1.1 mL
1.3.3 76 mg / 1.9 mL
1.4 Market Analysis by Dosage Form
1.4.1 Overview: Global Elrantamab Consumption Value by Dosage Form: 2021 Versus 2025 Versus 2032
1.4.2 Subcutaneous Injection Solution
1.4.3 Lyophilized Powder for Injection
1.5 Market Analysis by Sales Channels
1.5.1 Overview: Global Elrantamab Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
1.5.2 Hospital
1.5.3 Retail
1.5.4 Online
1.6 Market Analysis by Antibody Type
1.6.1 Overview: Global Elrantamab Consumption Value by Antibody Type: 2021 Versus 2025 Versus 2032
1.6.2 Monoclonal Antibody
1.6.3 Polyclonal Antibody
1.6.4 Bispecific Antibody
1.7 Market Analysis by Application
1.7.1 Overview: Global Elrantamab Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.7.2 Monotherapy for Relapsed or Refractory Multiple Myeloma
1.7.3 Combination Therapy with Immunomodulators and Proteasome Inhibitors
1.7.4 Exploration in First-Line or Second-Line Treatment of Multiple Myeloma
1.7.5 Otherts
1.8 Global Elrantamab Market Size & Forecast
1.8.1 Global Elrantamab Consumption Value (2021 & 2025 & 2032)
1.8.2 Global Elrantamab Sales Quantity (2021-2032)
1.8.3 Global Elrantamab Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Elrantamab Product and Services
2.1.4 Pfizer Elrantamab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Pfizer Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: ELRANTAMAB BY MANUFACTURER
3.1 Global Elrantamab Sales Quantity by Manufacturer (2021-2026)
3.2 Global Elrantamab Revenue by Manufacturer (2021-2026)
3.3 Global Elrantamab Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Elrantamab by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Elrantamab Manufacturer Market Share in 2025
3.4.3 Top 6 Elrantamab Manufacturer Market Share in 2025
3.5 Elrantamab Market: Overall Company Footprint Analysis
3.5.1 Elrantamab Market: Region Footprint
3.5.2 Elrantamab Market: Company Product Type Footprint
3.5.3 Elrantamab Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Elrantamab Market Size by Region
4.1.1 Global Elrantamab Sales Quantity by Region (2021-2032)
4.1.2 Global Elrantamab Consumption Value by Region (2021-2032)
4.1.3 Global Elrantamab Average Price by Region (2021-2032)
4.2 North America Elrantamab Consumption Value (2021-2032)
4.3 Europe Elrantamab Consumption Value (2021-2032)
4.4 Asia-Pacific Elrantamab Consumption Value (2021-2032)
4.5 South America Elrantamab Consumption Value (2021-2032)
4.6 Middle East & Africa Elrantamab Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global Elrantamab Sales Quantity by Type (2021-2032)
5.2 Global Elrantamab Consumption Value by Type (2021-2032)
5.3 Global Elrantamab Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Elrantamab Sales Quantity by Application (2021-2032)
6.2 Global Elrantamab Consumption Value by Application (2021-2032)
6.3 Global Elrantamab Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Elrantamab Sales Quantity by Type (2021-2032)
7.2 North America Elrantamab Sales Quantity by Application (2021-2032)
7.3 North America Elrantamab Market Size by Country
7.3.1 North America Elrantamab Sales Quantity by Country (2021-2032)
7.3.2 North America Elrantamab Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Elrantamab Sales Quantity by Type (2021-2032)
8.2 Europe Elrantamab Sales Quantity by Application (2021-2032)
8.3 Europe Elrantamab Market Size by Country
8.3.1 Europe Elrantamab Sales Quantity by Country (2021-2032)
8.3.2 Europe Elrantamab Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Elrantamab Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Elrantamab Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Elrantamab Market Size by Region
9.3.1 Asia-Pacific Elrantamab Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Elrantamab Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Elrantamab Sales Quantity by Type (2021-2032)
10.2 South America Elrantamab Sales Quantity by Application (2021-2032)
10.3 South America Elrantamab Market Size by Country
10.3.1 South America Elrantamab Sales Quantity by Country (2021-2032)
10.3.2 South America Elrantamab Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Elrantamab Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Elrantamab Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Elrantamab Market Size by Country
11.3.1 Middle East & Africa Elrantamab Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Elrantamab Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Elrantamab Market Drivers
12.2 Elrantamab Market Restraints
12.3 Elrantamab Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Elrantamab and Key Manufacturers
13.2 Manufacturing Costs Percentage of Elrantamab
13.3 Elrantamab Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Elrantamab Typical Distributors
14.3 Elrantamab Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Elrantamab Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Elrantamab Consumption Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Table 3. Global Elrantamab Consumption Value by Sales Channels, (USD Million), 2021 & 2025 & 2032
Table 4. Global Elrantamab Consumption Value by Antibody Type, (USD Million), 2021 & 2025 & 2032
Table 5. Global Elrantamab Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 6. Pfizer Basic Information, Manufacturing Base and Competitors
Table 7. Pfizer Major Business
Table 8. Pfizer Elrantamab Product and Services
Table 9. Pfizer Elrantamab Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 10. Pfizer Recent Developments/Updates
Table 11. Global Elrantamab Sales Quantity by Manufacturer (2021-2026) & (Units)
Table 12. Global Elrantamab Revenue by Manufacturer (2021-2026) & (USD Million)
Table 13. Global Elrantamab Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 14. Market Position of Manufacturers in Elrantamab, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 15. Head Office and Elrantamab Production Site of Key Manufacturer
Table 16. Elrantamab Market: Company Product Type Footprint
Table 17. Elrantamab Market: Company Product Application Footprint
Table 18. Elrantamab New Market Entrants and Barriers to Market Entry
Table 19. Elrantamab Mergers, Acquisition, Agreements, and Collaborations
Table 20. Global Elrantamab Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 21. Global Elrantamab Sales Quantity by Region (2021-2026) & (Units)
Table 22. Global Elrantamab Sales Quantity by Region (2027-2032) & (Units)
Table 23. Global Elrantamab Consumption Value by Region (2021-2026) & (USD Million)
Table 24. Global Elrantamab Consumption Value by Region (2027-2032) & (USD Million)
Table 25. Global Elrantamab Average Price by Region (2021-2026) & (US$/Unit)
Table 26. Global Elrantamab Average Price by Region (2027-2032) & (US$/Unit)
Table 27. Global Elrantamab Sales Quantity by Type (2021-2026) & (Units)
Table 28. Global Elrantamab Sales Quantity by Type (2027-2032) & (Units)
Table 29. Global Elrantamab Consumption Value by Type (2021-2026) & (USD Million)
Table 30. Global Elrantamab Consumption Value by Type (2027-2032) & (USD Million)
Table 31. Global Elrantamab Average Price by Type (2021-2026) & (US$/Unit)
Table 32. Global Elrantamab Average Price by Type (2027-2032) & (US$/Unit)
Table 33. Global Elrantamab Sales Quantity by Application (2021-2026) & (Units)
Table 34. Global Elrantamab Sales Quantity by Application (2027-2032) & (Units)
Table 35. Global Elrantamab Consumption Value by Application (2021-2026) & (USD Million)
Table 36. Global Elrantamab Consumption Value by Application (2027-2032) & (USD Million)
Table 37. Global Elrantamab Average Price by Application (2021-2026) & (US$/Unit)
Table 38. Global Elrantamab Average Price by Application (2027-2032) & (US$/Unit)
Table 39. North America Elrantamab Sales Quantity by Type (2021-2026) & (Units)
Table 40. North America Elrantamab Sales Quantity by Type (2027-2032) & (Units)
Table 41. North America Elrantamab Sales Quantity by Application (2021-2026) & (Units)
Table 42. North America Elrantamab Sales Quantity by Application (2027-2032) & (Units)
Table 43. North America Elrantamab Sales Quantity by Country (2021-2026) & (Units)
Table 44. North America Elrantamab Sales Quantity by Country (2027-2032) & (Units)
Table 45. North America Elrantamab Consumption Value by Country (2021-2026) & (USD Million)
Table 46. North America Elrantamab Consumption Value by Country (2027-2032) & (USD Million)
Table 47. Europe Elrantamab Sales Quantity by Type (2021-2026) & (Units)
Table 48. Europe Elrantamab Sales Quantity by Type (2027-2032) & (Units)
Table 49. Europe Elrantamab Sales Quantity by Application (2021-2026) & (Units)
Table 50. Europe Elrantamab Sales Quantity by Application (2027-2032) & (Units)
Table 51. Europe Elrantamab Sales Quantity by Country (2021-2026) & (Units)
Table 52. Europe Elrantamab Sales Quantity by Country (2027-2032) & (Units)
Table 53. Europe Elrantamab Consumption Value by Country (2021-2026) & (USD Million)
Table 54. Europe Elrantamab Consumption Value by Country (2027-2032) & (USD Million)
Table 55. Asia-Pacific Elrantamab Sales Quantity by Type (2021-2026) & (Units)
Table 56. Asia-Pacific Elrantamab Sales Quantity by Type (2027-2032) & (Units)
Table 57. Asia-Pacific Elrantamab Sales Quantity by Application (2021-2026) & (Units)
Table 58. Asia-Pacific Elrantamab Sales Quantity by Application (2027-2032) & (Units)
Table 59. Asia-Pacific Elrantamab Sales Quantity by Region (2021-2026) & (Units)
Table 60. Asia-Pacific Elrantamab Sales Quantity by Region (2027-2032) & (Units)
Table 61. Asia-Pacific Elrantamab Consumption Value by Region (2021-2026) & (USD Million)
Table 62. Asia-Pacific Elrantamab Consumption Value by Region (2027-2032) & (USD Million)
Table 63. South America Elrantamab Sales Quantity by Type (2021-2026) & (Units)
Table 64. South America Elrantamab Sales Quantity by Type (2027-2032) & (Units)
Table 65. South America Elrantamab Sales Quantity by Application (2021-2026) & (Units)
Table 66. South America Elrantamab Sales Quantity by Application (2027-2032) & (Units)
Table 67. South America Elrantamab Sales Quantity by Country (2021-2026) & (Units)
Table 68. South America Elrantamab Sales Quantity by Country (2027-2032) & (Units)
Table 69. South America Elrantamab Consumption Value by Country (2021-2026) & (USD Million)
Table 70. South America Elrantamab Consumption Value by Country (2027-2032) & (USD Million)
Table 71. Middle East & Africa Elrantamab Sales Quantity by Type (2021-2026) & (Units)
Table 72. Middle East & Africa Elrantamab Sales Quantity by Type (2027-2032) & (Units)
Table 73. Middle East & Africa Elrantamab Sales Quantity by Application (2021-2026) & (Units)
Table 74. Middle East & Africa Elrantamab Sales Quantity by Application (2027-2032) & (Units)
Table 75. Middle East & Africa Elrantamab Sales Quantity by Country (2021-2026) & (Units)
Table 76. Middle East & Africa Elrantamab Sales Quantity by Country (2027-2032) & (Units)
Table 77. Middle East & Africa Elrantamab Consumption Value by Country (2021-2026) & (USD Million)
Table 78. Middle East & Africa Elrantamab Consumption Value by Country (2027-2032) & (USD Million)
Table 79. Elrantamab Raw Material
Table 80. Key Manufacturers of Elrantamab Raw Materials
Table 81. Elrantamab Typical Distributors
Table 82. Elrantamab Typical Customers
Table 1. Global Elrantamab Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Elrantamab Consumption Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Table 3. Global Elrantamab Consumption Value by Sales Channels, (USD Million), 2021 & 2025 & 2032
Table 4. Global Elrantamab Consumption Value by Antibody Type, (USD Million), 2021 & 2025 & 2032
Table 5. Global Elrantamab Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 6. Pfizer Basic Information, Manufacturing Base and Competitors
Table 7. Pfizer Major Business
Table 8. Pfizer Elrantamab Product and Services
Table 9. Pfizer Elrantamab Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 10. Pfizer Recent Developments/Updates
Table 11. Global Elrantamab Sales Quantity by Manufacturer (2021-2026) & (Units)
Table 12. Global Elrantamab Revenue by Manufacturer (2021-2026) & (USD Million)
Table 13. Global Elrantamab Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 14. Market Position of Manufacturers in Elrantamab, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 15. Head Office and Elrantamab Production Site of Key Manufacturer
Table 16. Elrantamab Market: Company Product Type Footprint
Table 17. Elrantamab Market: Company Product Application Footprint
Table 18. Elrantamab New Market Entrants and Barriers to Market Entry
Table 19. Elrantamab Mergers, Acquisition, Agreements, and Collaborations
Table 20. Global Elrantamab Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 21. Global Elrantamab Sales Quantity by Region (2021-2026) & (Units)
Table 22. Global Elrantamab Sales Quantity by Region (2027-2032) & (Units)
Table 23. Global Elrantamab Consumption Value by Region (2021-2026) & (USD Million)
Table 24. Global Elrantamab Consumption Value by Region (2027-2032) & (USD Million)
Table 25. Global Elrantamab Average Price by Region (2021-2026) & (US$/Unit)
Table 26. Global Elrantamab Average Price by Region (2027-2032) & (US$/Unit)
Table 27. Global Elrantamab Sales Quantity by Type (2021-2026) & (Units)
Table 28. Global Elrantamab Sales Quantity by Type (2027-2032) & (Units)
Table 29. Global Elrantamab Consumption Value by Type (2021-2026) & (USD Million)
Table 30. Global Elrantamab Consumption Value by Type (2027-2032) & (USD Million)
Table 31. Global Elrantamab Average Price by Type (2021-2026) & (US$/Unit)
Table 32. Global Elrantamab Average Price by Type (2027-2032) & (US$/Unit)
Table 33. Global Elrantamab Sales Quantity by Application (2021-2026) & (Units)
Table 34. Global Elrantamab Sales Quantity by Application (2027-2032) & (Units)
Table 35. Global Elrantamab Consumption Value by Application (2021-2026) & (USD Million)
Table 36. Global Elrantamab Consumption Value by Application (2027-2032) & (USD Million)
Table 37. Global Elrantamab Average Price by Application (2021-2026) & (US$/Unit)
Table 38. Global Elrantamab Average Price by Application (2027-2032) & (US$/Unit)
Table 39. North America Elrantamab Sales Quantity by Type (2021-2026) & (Units)
Table 40. North America Elrantamab Sales Quantity by Type (2027-2032) & (Units)
Table 41. North America Elrantamab Sales Quantity by Application (2021-2026) & (Units)
Table 42. North America Elrantamab Sales Quantity by Application (2027-2032) & (Units)
Table 43. North America Elrantamab Sales Quantity by Country (2021-2026) & (Units)
Table 44. North America Elrantamab Sales Quantity by Country (2027-2032) & (Units)
Table 45. North America Elrantamab Consumption Value by Country (2021-2026) & (USD Million)
Table 46. North America Elrantamab Consumption Value by Country (2027-2032) & (USD Million)
Table 47. Europe Elrantamab Sales Quantity by Type (2021-2026) & (Units)
Table 48. Europe Elrantamab Sales Quantity by Type (2027-2032) & (Units)
Table 49. Europe Elrantamab Sales Quantity by Application (2021-2026) & (Units)
Table 50. Europe Elrantamab Sales Quantity by Application (2027-2032) & (Units)
Table 51. Europe Elrantamab Sales Quantity by Country (2021-2026) & (Units)
Table 52. Europe Elrantamab Sales Quantity by Country (2027-2032) & (Units)
Table 53. Europe Elrantamab Consumption Value by Country (2021-2026) & (USD Million)
Table 54. Europe Elrantamab Consumption Value by Country (2027-2032) & (USD Million)
Table 55. Asia-Pacific Elrantamab Sales Quantity by Type (2021-2026) & (Units)
Table 56. Asia-Pacific Elrantamab Sales Quantity by Type (2027-2032) & (Units)
Table 57. Asia-Pacific Elrantamab Sales Quantity by Application (2021-2026) & (Units)
Table 58. Asia-Pacific Elrantamab Sales Quantity by Application (2027-2032) & (Units)
Table 59. Asia-Pacific Elrantamab Sales Quantity by Region (2021-2026) & (Units)
Table 60. Asia-Pacific Elrantamab Sales Quantity by Region (2027-2032) & (Units)
Table 61. Asia-Pacific Elrantamab Consumption Value by Region (2021-2026) & (USD Million)
Table 62. Asia-Pacific Elrantamab Consumption Value by Region (2027-2032) & (USD Million)
Table 63. South America Elrantamab Sales Quantity by Type (2021-2026) & (Units)
Table 64. South America Elrantamab Sales Quantity by Type (2027-2032) & (Units)
Table 65. South America Elrantamab Sales Quantity by Application (2021-2026) & (Units)
Table 66. South America Elrantamab Sales Quantity by Application (2027-2032) & (Units)
Table 67. South America Elrantamab Sales Quantity by Country (2021-2026) & (Units)
Table 68. South America Elrantamab Sales Quantity by Country (2027-2032) & (Units)
Table 69. South America Elrantamab Consumption Value by Country (2021-2026) & (USD Million)
Table 70. South America Elrantamab Consumption Value by Country (2027-2032) & (USD Million)
Table 71. Middle East & Africa Elrantamab Sales Quantity by Type (2021-2026) & (Units)
Table 72. Middle East & Africa Elrantamab Sales Quantity by Type (2027-2032) & (Units)
Table 73. Middle East & Africa Elrantamab Sales Quantity by Application (2021-2026) & (Units)
Table 74. Middle East & Africa Elrantamab Sales Quantity by Application (2027-2032) & (Units)
Table 75. Middle East & Africa Elrantamab Sales Quantity by Country (2021-2026) & (Units)
Table 76. Middle East & Africa Elrantamab Sales Quantity by Country (2027-2032) & (Units)
Table 77. Middle East & Africa Elrantamab Consumption Value by Country (2021-2026) & (USD Million)
Table 78. Middle East & Africa Elrantamab Consumption Value by Country (2027-2032) & (USD Million)
Table 79. Elrantamab Raw Material
Table 80. Key Manufacturers of Elrantamab Raw Materials
Table 81. Elrantamab Typical Distributors
Table 82. Elrantamab Typical Customers
LIST OF FIGURES
Figure 1. Elrantamab Picture
Figure 2. Global Elrantamab Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Elrantamab Revenue Market Share by Type in 2025
Figure 4. 44 mg / 1.1 mL Examples
Figure 5. 76 mg / 1.9 mL Examples
Figure 6. Global Elrantamab Revenue by Dosage Form, (USD Million), 2021 & 2025 & 2032
Figure 7. Global Elrantamab Revenue Market Share by Dosage Form in 2025
Figure 8. Subcutaneous Injection Solution Examples
Figure 9. Lyophilized Powder for Injection Examples
Figure 10. Global Elrantamab Revenue by Sales Channels, (USD Million), 2021 & 2025 & 2032
Figure 11. Global Elrantamab Revenue Market Share by Sales Channels in 2025
Figure 12. Hospital Examples
Figure 13. Retail Examples
Figure 14. Online Examples
Figure 15. Global Elrantamab Revenue by Antibody Type, (USD Million), 2021 & 2025 & 2032
Figure 16. Global Elrantamab Revenue Market Share by Antibody Type in 2025
Figure 17. Monoclonal Antibody Examples
Figure 18. Polyclonal Antibody Examples
Figure 19. Bispecific Antibody Examples
Figure 20. Global Elrantamab Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 21. Global Elrantamab Revenue Market Share by Application in 2025
Figure 22. Monotherapy for Relapsed or Refractory Multiple Myeloma Examples
Figure 23. Combination Therapy with Immunomodulators and Proteasome Inhibitors Examples
Figure 24. Exploration in First-Line or Second-Line Treatment of Multiple Myeloma Examples
Figure 25. Otherts Examples
Figure 26. Global Elrantamab Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 27. Global Elrantamab Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 28. Global Elrantamab Sales Quantity (2021-2032) & (Units)
Figure 29. Global Elrantamab Price (2021-2032) & (US$/Unit)
Figure 30. Global Elrantamab Sales Quantity Market Share by Manufacturer in 2025
Figure 31. Global Elrantamab Revenue Market Share by Manufacturer in 2025
Figure 32. Producer Shipments of Elrantamab by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 33. Top 3 Elrantamab Manufacturer (Revenue) Market Share in 2025
Figure 34. Top 6 Elrantamab Manufacturer (Revenue) Market Share in 2025
Figure 35. Global Elrantamab Sales Quantity Market Share by Region (2021-2032)
Figure 36. Global Elrantamab Consumption Value Market Share by Region (2021-2032)
Figure 37. North America Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 38. Europe Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 39. Asia-Pacific Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 40. South America Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 41. Middle East & Africa Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 42. Global Elrantamab Sales Quantity Market Share by Type (2021-2032)
Figure 43. Global Elrantamab Consumption Value Market Share by Type (2021-2032)
Figure 44. Global Elrantamab Average Price by Type (2021-2032) & (US$/Unit)
Figure 45. Global Elrantamab Sales Quantity Market Share by Application (2021-2032)
Figure 46. Global Elrantamab Revenue Market Share by Application (2021-2032)
Figure 47. Global Elrantamab Average Price by Application (2021-2032) & (US$/Unit)
Figure 48. North America Elrantamab Sales Quantity Market Share by Type (2021-2032)
Figure 49. North America Elrantamab Sales Quantity Market Share by Application (2021-2032)
Figure 50. North America Elrantamab Sales Quantity Market Share by Country (2021-2032)
Figure 51. North America Elrantamab Consumption Value Market Share by Country (2021-2032)
Figure 52. United States Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 53. Canada Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 54. Mexico Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 55. Europe Elrantamab Sales Quantity Market Share by Type (2021-2032)
Figure 56. Europe Elrantamab Sales Quantity Market Share by Application (2021-2032)
Figure 57. Europe Elrantamab Sales Quantity Market Share by Country (2021-2032)
Figure 58. Europe Elrantamab Consumption Value Market Share by Country (2021-2032)
Figure 59. Germany Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 60. France Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 61. United Kingdom Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 62. Russia Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 63. Italy Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 64. Asia-Pacific Elrantamab Sales Quantity Market Share by Type (2021-2032)
Figure 65. Asia-Pacific Elrantamab Sales Quantity Market Share by Application (2021-2032)
Figure 66. Asia-Pacific Elrantamab Sales Quantity Market Share by Region (2021-2032)
Figure 67. Asia-Pacific Elrantamab Consumption Value Market Share by Region (2021-2032)
Figure 68. China Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 69. Japan Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 70. South Korea Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 71. India Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 72. Southeast Asia Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 73. Australia Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 74. South America Elrantamab Sales Quantity Market Share by Type (2021-2032)
Figure 75. South America Elrantamab Sales Quantity Market Share by Application (2021-2032)
Figure 76. South America Elrantamab Sales Quantity Market Share by Country (2021-2032)
Figure 77. South America Elrantamab Consumption Value Market Share by Country (2021-2032)
Figure 78. Brazil Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 79. Argentina Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 80. Middle East & Africa Elrantamab Sales Quantity Market Share by Type (2021-2032)
Figure 81. Middle East & Africa Elrantamab Sales Quantity Market Share by Application (2021-2032)
Figure 82. Middle East & Africa Elrantamab Sales Quantity Market Share by Country (2021-2032)
Figure 83. Middle East & Africa Elrantamab Consumption Value Market Share by Country (2021-2032)
Figure 84. Turkey Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 85. Egypt Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 86. Saudi Arabia Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 87. South Africa Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 88. Elrantamab Market Drivers
Figure 89. Elrantamab Market Restraints
Figure 90. Elrantamab Market Trends
Figure 91. Porters Five Forces Analysis
Figure 92. Manufacturing Cost Structure Analysis of Elrantamab in 2025
Figure 93. Manufacturing Process Analysis of Elrantamab
Figure 94. Elrantamab Industrial Chain
Figure 95. Sales Channel: Direct to End-User vs Distributors
Figure 96. Direct Channel Pros & Cons
Figure 97. Indirect Channel Pros & Cons
Figure 98. Methodology
Figure 99. Research Process and Data Source
Figure 1. Elrantamab Picture
Figure 2. Global Elrantamab Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Elrantamab Revenue Market Share by Type in 2025
Figure 4. 44 mg / 1.1 mL Examples
Figure 5. 76 mg / 1.9 mL Examples
Figure 6. Global Elrantamab Revenue by Dosage Form, (USD Million), 2021 & 2025 & 2032
Figure 7. Global Elrantamab Revenue Market Share by Dosage Form in 2025
Figure 8. Subcutaneous Injection Solution Examples
Figure 9. Lyophilized Powder for Injection Examples
Figure 10. Global Elrantamab Revenue by Sales Channels, (USD Million), 2021 & 2025 & 2032
Figure 11. Global Elrantamab Revenue Market Share by Sales Channels in 2025
Figure 12. Hospital Examples
Figure 13. Retail Examples
Figure 14. Online Examples
Figure 15. Global Elrantamab Revenue by Antibody Type, (USD Million), 2021 & 2025 & 2032
Figure 16. Global Elrantamab Revenue Market Share by Antibody Type in 2025
Figure 17. Monoclonal Antibody Examples
Figure 18. Polyclonal Antibody Examples
Figure 19. Bispecific Antibody Examples
Figure 20. Global Elrantamab Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 21. Global Elrantamab Revenue Market Share by Application in 2025
Figure 22. Monotherapy for Relapsed or Refractory Multiple Myeloma Examples
Figure 23. Combination Therapy with Immunomodulators and Proteasome Inhibitors Examples
Figure 24. Exploration in First-Line or Second-Line Treatment of Multiple Myeloma Examples
Figure 25. Otherts Examples
Figure 26. Global Elrantamab Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 27. Global Elrantamab Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 28. Global Elrantamab Sales Quantity (2021-2032) & (Units)
Figure 29. Global Elrantamab Price (2021-2032) & (US$/Unit)
Figure 30. Global Elrantamab Sales Quantity Market Share by Manufacturer in 2025
Figure 31. Global Elrantamab Revenue Market Share by Manufacturer in 2025
Figure 32. Producer Shipments of Elrantamab by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 33. Top 3 Elrantamab Manufacturer (Revenue) Market Share in 2025
Figure 34. Top 6 Elrantamab Manufacturer (Revenue) Market Share in 2025
Figure 35. Global Elrantamab Sales Quantity Market Share by Region (2021-2032)
Figure 36. Global Elrantamab Consumption Value Market Share by Region (2021-2032)
Figure 37. North America Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 38. Europe Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 39. Asia-Pacific Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 40. South America Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 41. Middle East & Africa Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 42. Global Elrantamab Sales Quantity Market Share by Type (2021-2032)
Figure 43. Global Elrantamab Consumption Value Market Share by Type (2021-2032)
Figure 44. Global Elrantamab Average Price by Type (2021-2032) & (US$/Unit)
Figure 45. Global Elrantamab Sales Quantity Market Share by Application (2021-2032)
Figure 46. Global Elrantamab Revenue Market Share by Application (2021-2032)
Figure 47. Global Elrantamab Average Price by Application (2021-2032) & (US$/Unit)
Figure 48. North America Elrantamab Sales Quantity Market Share by Type (2021-2032)
Figure 49. North America Elrantamab Sales Quantity Market Share by Application (2021-2032)
Figure 50. North America Elrantamab Sales Quantity Market Share by Country (2021-2032)
Figure 51. North America Elrantamab Consumption Value Market Share by Country (2021-2032)
Figure 52. United States Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 53. Canada Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 54. Mexico Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 55. Europe Elrantamab Sales Quantity Market Share by Type (2021-2032)
Figure 56. Europe Elrantamab Sales Quantity Market Share by Application (2021-2032)
Figure 57. Europe Elrantamab Sales Quantity Market Share by Country (2021-2032)
Figure 58. Europe Elrantamab Consumption Value Market Share by Country (2021-2032)
Figure 59. Germany Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 60. France Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 61. United Kingdom Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 62. Russia Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 63. Italy Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 64. Asia-Pacific Elrantamab Sales Quantity Market Share by Type (2021-2032)
Figure 65. Asia-Pacific Elrantamab Sales Quantity Market Share by Application (2021-2032)
Figure 66. Asia-Pacific Elrantamab Sales Quantity Market Share by Region (2021-2032)
Figure 67. Asia-Pacific Elrantamab Consumption Value Market Share by Region (2021-2032)
Figure 68. China Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 69. Japan Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 70. South Korea Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 71. India Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 72. Southeast Asia Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 73. Australia Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 74. South America Elrantamab Sales Quantity Market Share by Type (2021-2032)
Figure 75. South America Elrantamab Sales Quantity Market Share by Application (2021-2032)
Figure 76. South America Elrantamab Sales Quantity Market Share by Country (2021-2032)
Figure 77. South America Elrantamab Consumption Value Market Share by Country (2021-2032)
Figure 78. Brazil Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 79. Argentina Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 80. Middle East & Africa Elrantamab Sales Quantity Market Share by Type (2021-2032)
Figure 81. Middle East & Africa Elrantamab Sales Quantity Market Share by Application (2021-2032)
Figure 82. Middle East & Africa Elrantamab Sales Quantity Market Share by Country (2021-2032)
Figure 83. Middle East & Africa Elrantamab Consumption Value Market Share by Country (2021-2032)
Figure 84. Turkey Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 85. Egypt Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 86. Saudi Arabia Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 87. South Africa Elrantamab Consumption Value (2021-2032) & (USD Million)
Figure 88. Elrantamab Market Drivers
Figure 89. Elrantamab Market Restraints
Figure 90. Elrantamab Market Trends
Figure 91. Porters Five Forces Analysis
Figure 92. Manufacturing Cost Structure Analysis of Elrantamab in 2025
Figure 93. Manufacturing Process Analysis of Elrantamab
Figure 94. Elrantamab Industrial Chain
Figure 95. Sales Channel: Direct to End-User vs Distributors
Figure 96. Direct Channel Pros & Cons
Figure 97. Indirect Channel Pros & Cons
Figure 98. Methodology
Figure 99. Research Process and Data Source
